Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2009, Article ID 649286, 7 pages
Research Article

The Role of the PGC1 Gly482Ser Polymorphism in Weight Gain due to Intensive Diabetes Therapy

1Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA 98195-7720, USA
2Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle, WA 98195-7720, USA

Received 13 December 2008; Accepted 14 January 2009

Academic Editor: Marie-Claude Vohl

Copyright © 2009 Samir S. Deeb and John D. Brunzell. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The Diabetes Control and Complications Trial (DCCT) involved intensive diabetes therapy of subjects with type 1 diabetes mellitus (T1DM) for an average period of 6.5 years. A subset of these subjects gained excessive weight. We tested for association of polymorphisms in 8 candidate genes with the above trait. We found the Gly482Ser polymorphism in the peroxisome proliferator-activated receptor coactivator-1 (PGC1 ) to be significantly associated with weight gain in males ( ) but not in females. The Ser allele was associated with greater weight gain than the Gly allele ( ). Subjects with a family history of type 2 diabetes mellitus (T2DM) were more common among those who gained excessive weight. We conclude that T2DM and the Gly482Ser polymorphism in PGC1 contribute to the effect of intensive diabetes therapy on weight gain in males with T1DM.